<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02797717</url>
  </required_header>
  <id_info>
    <org_study_id>scmci160509ctil</org_study_id>
    <nct_id>NCT02797717</nct_id>
  </id_info>
  <brief_title>Treatment for Classical Hodgkin Lymphoma in Children and Adolescents</brief_title>
  <acronym>EuroNet-PHL-C2</acronym>
  <official_title>An International, Multicentre, Randomised Controlled Trial. Treatment for Classical Hodgkin Lymphoma in Children and Adolescents Standard Treatment (Chemotherapy and RT) Compared With Experimental Treatment (Chemotherapy Without RT or Restricted to RT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GALIA AVRAHAMI</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Giessen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Reduction of the indication for radiotherapy (RT) in newly diagnosed patients with classical
      Hodgkins lymphoma without compromising cure rates. Investigation of a chemotherapy
      intensification randomisation in intermediate and advanced classical Hodgkins lymphoma
      patients to compensate for reduction in RT.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase event free survival rate from 88% to 93%</measure>
    <time_frame>Will be assessed once a year up to 5 years after end of treatment.</time_frame>
    <description>Methods of measurement: chest X-ray; US neck, abdomen and pelvis; lung function; T4,Throid Stimulating Hormone ,US of thyroid; MRI of initially involved region; chest CT in patients with initial lung involvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>comparison of haematotoxicity between arm A and arm B</measure>
    <time_frame>Will be assessed in day 0,day 8,day 11,day 17 and day 21 of each cycle</time_frame>
    <description>Evaluation of haematotoxicity by documentation of blood count courses during &quot;OEPA&quot;, COPDAC-28 and DECOPDAC-21 cycles. Comparison between COPDAC-28 versus DECOPDAC-21.
For ERA(early response assessment) PET(Positron Emission Tomography)-positive patients to compare to the LRA (late response assessment)PET-positivity rates after consolidation chemotherapy with COPDAC-28 or DECOPDAC-21.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2200</enrollment>
  <condition>Classical Hodgkins Lymphoma in Children and Adolescents.</condition>
  <arm_group>
    <arm_group_label>A-&quot;COPDAC-28&quot;</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>standard COPDAC-28 (chemotherapy cycle:Cyclophosphamide,Doxorubicin,Prednisone,Dacarbazine), chemotherapy and standard involved node radiotherapy.
drugs: Prednisone 40mg/m2/day,P.O,day 1-day 15. Dacarbazine 250mg/m2, I.V. , infusion,day 1- day 3. Vincristine 15mg/m2 , I.V. , day1+day 8. Cyclophosphamide 500mg/m2,infusion,day 1+day 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B- &quot;DECOPDAC-21&quot;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DECOPDAC-21(chemotherapy cycle:Dacarbazine,Etoposide,Doxorubicin,Cyclophosphamide,Prednisone,Vincristine) intensified chemotherapy and no RT or restricted fields of radiotherapy.
Drugs: Prednisone 40mg/m2/day,P.O,day 1-day 15:
Dacarbazine 250mg/m2, I.V. , infusion,day 1- day 3 Vincristine 15mg/m2 , I.V. , day1+day 8 Cyclophosphamide 625mg/m2,infusion,day1+day2 Etoposide 100mg/m2/day,infusion,day 1- day 3 Doxorubicin 25mg/m2, infusion, day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy:</intervention_name>
    <description>All patients will have 2 &quot;OPEA&quot;cycles(chemotherapy cycle:Vincristine,Etoposide,Prednisone,doxorubicin) ,After assignment ( by randomization) to one of the arms the patient will be treated accordingly . response assessment will be done after &quot;OPEA&quot; cycles (ERA) and after cycles of &quot;copdac 28&quot; or DECOPDAC 21(LRA).according to the assessments results patients will have radiotherapy or not.</description>
    <arm_group_label>A-&quot;COPDAC-28&quot;</arm_group_label>
    <arm_group_label>B- &quot;DECOPDAC-21&quot;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>ARM A and ARM B</description>
    <arm_group_label>A-&quot;COPDAC-28&quot;</arm_group_label>
    <arm_group_label>B- &quot;DECOPDAC-21&quot;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>ARM B , 100mg/m2/day</description>
    <arm_group_label>B- &quot;DECOPDAC-21&quot;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>ARM A and ARM B , 40mg/m2/day p.o</description>
    <arm_group_label>A-&quot;COPDAC-28&quot;</arm_group_label>
    <arm_group_label>B- &quot;DECOPDAC-21&quot;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>ARM B , 25mg/m2</description>
    <arm_group_label>B- &quot;DECOPDAC-21&quot;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dacarbazine</intervention_name>
    <description>ARM A and ARM B , 250mg/m2 i.v</description>
    <arm_group_label>A-&quot;COPDAC-28&quot;</arm_group_label>
    <arm_group_label>B- &quot;DECOPDAC-21&quot;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>ARM A and ARM B , 625mg/m2 i.v</description>
    <arm_group_label>A-&quot;COPDAC-28&quot;</arm_group_label>
    <arm_group_label>B- &quot;DECOPDAC-21&quot;</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. histologically confirmed primary diagnosis of classical Hodgkin's lymphoma.

          2. patients under 18 years of age on the date of written informed consent. In specialized
             Teenage and Young Adult (TYA) units in Australia, France, Italy, New Zealand and
             United Kingdom patients up to under 25 years of age can also be enrolled. Lower age
             limits will be country specific according to national laws or formal insurance
             requirements that may preclude very young patients.

          3. written informed consent of the patient and/or the patient's parents or guardian
             according to national laws.

          4. negative pregnancy test within 2 weeks prior to starting treatment for female patients
             with childbearing potential

        Exclusion Criteria: (Patients with one or more of the following criterion are excluded)

          1. prior chemotherapy or radiotherapy for other malignancies

          2. pre-treatment of Hodgkin's lymphoma (except for steroid pre-phase to a maximum of 7-10
             days for emergency treatment of a large mediastinal tumour).

          3. diagnosis of lymphocyte-predominant Hodgkin's lymphoma

          4. other (simultaneous) malignancies

          5. contraindication or known hypersensitivity to study drugs

          6. severe concomitant diseases (e.g. immune deficiency syndrome)

          7. known HIV-positivity

          8. residence outside the participating countries where long term follow-up cannot be
             guaranteed

          9. pregnancy and / or lactation

         10. patients who are sexually active and are unwilling to use adequate contraception
             during therapy and for one month after last trial treatment

         11. current or recent (within 30 days prior to date of written informed consent) treatment
             with another investigational drug or participation in another interventional clinical
             trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dieter K.rholz, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Universit.tsklinikum Giessen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Galia Avrahami, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Schneider children medical center,Kaplan 14 Petach-Tikva,Israel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Galia Avrahami, MD</last_name>
    <phone>972-3-9253356</phone>
    <email>Galia2@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michal Rada</last_name>
    <phone>972-524-643166</phone>
    <email>michalra6@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Schneider children's medical center</name>
      <address>
        <city>Petach-Tikva</city>
        <zip>4920235</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galia Avrahami, MD</last_name>
      <phone>972-3-9253356</phone>
      <email>Galia2@clalit.org.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2016</study_first_submitted>
  <study_first_submitted_qc>June 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2016</study_first_posted>
  <last_update_submitted>June 13, 2016</last_update_submitted>
  <last_update_submitted_qc>June 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rabin Medical Center</investigator_affiliation>
    <investigator_full_name>GALIA AVRAHAMI</investigator_full_name>
    <investigator_title>Senior pediatric oncologist physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

